Annual EBITDA
-$25.39 M
+$3.08 M+10.83%
December 31, 2023
Summary
- As of February 8, 2025, CMMB annual EBITDA is -$25.39 million, with the most recent change of +$3.08 million (+10.83%) on December 31, 2023.
- During the last 3 years, CMMB annual EBITDA has fallen by -$19.44 million (-326.90%).
- CMMB annual EBITDA is now -326.90% below its all-time high of -$5.95 million, reached on December 31, 2020.
Performance
CMMB EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$3.71 M
+$58.00 K+1.54%
September 1, 2024
Summary
- As of February 8, 2025, CMMB quarterly EBITDA is -$3.71 million, with the most recent change of +$58.00 thousand (+1.54%) on September 1, 2024.
- Over the past year, CMMB quarterly EBITDA has increased by +$58.00 thousand (+1.54%).
- CMMB quarterly EBITDA is now -238.50% below its all-time high of -$1.10 million, reached on June 30, 2020.
Performance
CMMB Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$15.37 M
+$657.00 K+4.10%
September 1, 2024
Summary
- As of February 8, 2025, CMMB TTM EBITDA is -$15.37 million, with the most recent change of +$657.00 thousand (+4.10%) on September 1, 2024.
- Over the past year, CMMB TTM EBITDA has increased by +$657.00 thousand (+4.10%).
- CMMB TTM EBITDA is now -804.89% below its all-time high of -$1.70 million, reached on March 31, 2020.
Performance
CMMB TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
CMMB EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +10.8% | +1.5% | +4.1% |
| 3 y3 years | -326.9% | +1.5% | +4.1% |
| 5 y5 years | -326.9% | +1.5% | +4.1% |
CMMB EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -105.9% | +10.8% | at high | +58.9% | -24.7% | +55.0% |
| 5 y | 5-year | -326.9% | +10.8% | -238.5% | +58.9% | -804.9% | +55.0% |
| alltime | all time | -326.9% | +10.8% | -238.5% | +58.9% | -804.9% | +55.0% |
Chemomab Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.71 M(-1.5%) | -$15.37 M(-4.1%) |
| Jun 2024 | - | -$3.77 M(-6.9%) | -$16.03 M(-21.6%) |
| Mar 2024 | - | -$4.05 M(+5.2%) | -$20.44 M(-19.6%) |
| Dec 2023 | -$25.39 M(-10.8%) | -$3.85 M(-11.9%) | -$25.43 M(-15.8%) |
| Sep 2023 | - | -$4.37 M(-46.6%) | -$30.21 M(-11.5%) |
| Jun 2023 | - | -$8.18 M(-9.5%) | -$34.14 M(+6.0%) |
| Mar 2023 | - | -$9.03 M(+4.7%) | -$32.20 M(+13.1%) |
| Dec 2022 | -$28.48 M | -$8.63 M(+4.0%) | -$28.48 M(+14.5%) |
| Sep 2022 | - | -$8.30 M(+33.0%) | -$24.86 M(+27.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | -$6.24 M(+17.6%) | -$19.44 M(+21.9%) |
| Mar 2022 | - | -$5.31 M(+5.9%) | -$15.95 M(+29.3%) |
| Dec 2021 | -$12.33 M(+107.3%) | -$5.01 M(+73.9%) | -$12.33 M(+33.2%) |
| Sep 2021 | - | -$2.88 M(+5.0%) | -$9.26 M(+21.9%) |
| Jun 2021 | - | -$2.75 M(+62.3%) | -$7.59 M(+27.8%) |
| Mar 2021 | - | -$1.69 M(-12.6%) | -$5.94 M(-0.1%) |
| Dec 2020 | -$5.95 M | -$1.94 M(+59.1%) | -$5.95 M(+48.3%) |
| Sep 2020 | - | -$1.22 M(+11.0%) | -$4.01 M(+43.5%) |
| Jun 2020 | - | -$1.10 M(-35.5%) | -$2.79 M(+64.5%) |
| Mar 2020 | - | -$1.70 M | -$1.70 M |
FAQ
- What is Chemomab Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Chemomab Therapeutics?
- What is Chemomab Therapeutics annual EBITDA year-on-year change?
- What is Chemomab Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Chemomab Therapeutics?
- What is Chemomab Therapeutics quarterly EBITDA year-on-year change?
- What is Chemomab Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Chemomab Therapeutics?
- What is Chemomab Therapeutics TTM EBITDA year-on-year change?
What is Chemomab Therapeutics annual EBITDA?
The current annual EBITDA of CMMB is -$25.39 M
What is the all time high annual EBITDA for Chemomab Therapeutics?
Chemomab Therapeutics all-time high annual EBITDA is -$5.95 M
What is Chemomab Therapeutics annual EBITDA year-on-year change?
Over the past year, CMMB annual EBITDA has changed by +$3.08 M (+10.83%)
What is Chemomab Therapeutics quarterly EBITDA?
The current quarterly EBITDA of CMMB is -$3.71 M
What is the all time high quarterly EBITDA for Chemomab Therapeutics?
Chemomab Therapeutics all-time high quarterly EBITDA is -$1.10 M
What is Chemomab Therapeutics quarterly EBITDA year-on-year change?
Over the past year, CMMB quarterly EBITDA has changed by +$58.00 K (+1.54%)
What is Chemomab Therapeutics TTM EBITDA?
The current TTM EBITDA of CMMB is -$15.37 M
What is the all time high TTM EBITDA for Chemomab Therapeutics?
Chemomab Therapeutics all-time high TTM EBITDA is -$1.70 M
What is Chemomab Therapeutics TTM EBITDA year-on-year change?
Over the past year, CMMB TTM EBITDA has changed by +$657.00 K (+4.10%)